This is also the structure Novo Nordisk's own investigational semaglutide+cagrilintide combination used in REDEFINE 1 (Garvey et al., NEJM 2025) both components stepped in parallel through a 16-week ramp rather than introduced together at maintenance
Powered by innovative Tri-tab technology, it ensures optimized drug delivery, better cardioprotection, and consistent outcomes for patients with complex cardiovascular needs
This endeavor not only aligns with the scientific pursuit of knowledge, but also directly addresses the concerns raised by the reviewers, ensuring that the discussion is both comprehensive and relevant to the broader context of cancer treatment
Research suggests that GIP receptor activation contributes significantly to fat metabolism and energy expenditure in ways that GLP-1 alone does not address
Unless your clinician has identified a deficiency state (dialysis, genetic disorder), there is no established benefit and no evidence it enhances GLP-1 therapy